



Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 28, 2025-- [Vistagen](#) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at Jefferies 2025 Global Life Sciences Conference in New York.

Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat on Thursday, June 5, at 11:40 a.m. Eastern Time.

The presentation will be accessible via a live webcast on the [Events](#) page in the Investors section of Vistagen's website and a replay will be available following the presentation.

About Vistagen

Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal therapies called pherines. Pherines specifically and selectively bind as agonists to peripheral receptors in human nasal chemosensory neurons, designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options. Vistagen's neuroscience pipeline also includes an oral prodrug with potential to impact certain neurological conditions involving the NMDA receptor.

Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at www.Vistagen.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250528350523/en/): <https://www.businesswire.com/news/home/20250528350523/en/>

Investor Inquiries:

Mark A. McPartland
markmcp@vistagen.com

Media Inquiries:

Michelle P. Wellington
mwellington@vistagen.com

Source: Vistagen